High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer

Estrogen receptor-positive (ER+) breast cancer intrinsically confers satisfactory clinical outcomes in response to endocrine therapy. However, a significant proportion of patients with ER+ breast cancer do not respond well to this treatment. Therefore, to evaluate the effects of endocrine therapy, t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2022-05, Vol.17 (5), p.e0268799-e0268799
Hauptverfasser:	Onaga, Chotaro, Tamori, Shoma, Matsuoka, Izumi, Ozaki, Ayaka, Motomura, Hitomi, Nagashima, Yuka, Sato, Tsugumichi, Sato, Keiko, Xiong, Yuyun, Sasaki, Kazunori, Ohno, Shigeo, Akimoto, Kazunori
Format:	Artikel
Sprache:	eng
Schlagworte:	Biology and Life Sciences Biomarkers Breast cancer Cancer therapies Cell cycle Chemotherapy Clinical outcomes Complications and side effects Consortia Datasets Diagnosis Endocrine therapy Estrogen receptors Estrogens Evaluation Gene expression Genetic aspects Hormone therapy Medical prognosis Medicine and Health Sciences Patient outcomes Patients Physical Sciences Regression analysis Research and Analysis Methods Sodium Subgroups Taxonomy Tumor staging Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!